(Q34288852)

1 August 2017

title

Buprenorphine for opiate addiction: potential economic impact (English)

1 reference

1 August 2017

1 reference

Rosenheck R

1

1 reference

1 August 2017

Kosten T

series ordinal

2

1 reference

1 August 2017

publication date

1 August 2001

1 reference

Drug and Alcohol Dependence

1 August 2017

published in

1 reference

1 August 2017

volume

63

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

253-262

1 reference

Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

Financing and cost of standard and enhanced methadone treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

Comparing opiate users in methadone treatment with untreated opiate users: results of a follow-up study with a Toronto opiate user cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

The value of mental health care at the system level: the case of treating depression

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

The effects of time in drug abuse treatment and employment on posttreatment drug use and criminal activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

Estimating the dollar value of health outcomes from drug-abuse interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

A structured instrument for estimating the economic cost of drug abuse treatment. The Drug Abuse Treatment Cost Analysis Program (DATCAP).

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

A cost-effectiveness and cost-benefit analysis of contingency contracting-enhanced methadone detoxification treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

Trends in medical use and abuse of opioid analgesics

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

Are supplementary services provided during methadone maintenance really cost-effective?

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

Cost-effectiveness of services for mentally ill homeless people: the application of research to policy and practice

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

Cost-effectiveness of intensive psychiatric community care for high users of inpatient services.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

Who should receive high-cost mental health treatment and for how long?

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

Issues in estimating the cost of innovative mental health programs.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

Comparison of buprenorphine and methadone in the treatment of opioid dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

Effects of adding behavioral treatment to opioid detoxification with buprenorphine

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2800%2900214-3

7 January 2021

10.1016/S0376-8716(00)00214-3

Identifiers

DOI

1 reference

1 August 2017

1 reference